Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Verastem Trumpets Early Clinical Results For FAK Program, Discloses Timelines And Plans

This article was originally published in The Pink Sheet Daily

Executive Summary

Addressing an audience of 150 attendees at its first clinical-stage R&D day on July 11, Verastem Inc. put forward its new senior executive team, as well as an eminent authority in cancer stem cell biology, to describe its clinical progress thus far, and its future plans.

You may also be interested in...

Verastem Catapults To Mid-stage Development with Pfizer Licensing Deal

The Massachusetts-based cancer stem cell company has struck two deals in as many days in an effort to move compounds into the clinic for various types of cancers and multiple targets.

The HDAC Field Heats Up: An Interview with Syndax CEO Joanna Horobin

Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?

Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts